GeneDx Holdings (WGS) Gross Profit (2020 - 2026)

GeneDx Holdings has disclosed Gross Profit across 7 years of filings, most recently posting $68.2 million for Q1 2026.

• In Q1 2026, Gross Profit rose 16.65% year-over-year to $68.2 million; the TTM figure through Mar 2026 stood at $307.9 million (up 42.91% YoY), while the FY2025 annual figure was $298.2 million, up 53.38% from the prior year.
• Gross Profit eased to $68.2 million in Q1 2026, from $84.3 million in the prior quarter.
• Over the last five years, Gross Profit for WGS reached as high as $84.5 million in Q3 2025 and fell as low as -$29.6 million in Q2 2022.
• The 5-year median for Gross Profit is $37.4 million (2024), against an average of $36.7 million.
• Annual changes were most pronounced in 2022 — Gross Profit plunged 2442.78% — and 2023, when it soared 288.37%.
• A 5-year view of Gross Profit shows it stood at -$16.3 million in 2022, then soared by 288.37% to $30.8 million in 2023, then jumped by 115.27% to $66.2 million in 2024, then grew by 27.28% to $84.3 million in 2025, then decreased by 19.05% to $68.2 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $68.2 million, $84.3 million, and $84.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.